Assessing the value of new cancer drugs for regulatory and HTA decisions e the role of ESMO-MCBS

被引：0
|
作者：
Gyawali, B. [1 ]
机构：
[1] Queens Univ, Dept Oncol, Kingston, ON, Canada
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.07.309
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EJS-2
引用
收藏
页码：S1277 / S1277
页数：1
相关论文
共 11 条
  • [1] Is there a link between value as defined by ESMO-MCBS and uptake of new drugs?
    Lindgren, Peter
    Jonsson, Bengt
    Hofmarcher, Thomas
    Wilking, Nils Erik
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] ESMO-MCBS and health technology assessment (HTA): Does value for physicians correspond to value for payers?
    Ambavane, A.
    Benedict, A.
    Rivolo, S.
    Rakonczai, P.
    Kapetanakis, V.
    ANNALS OF ONCOLOGY, 2019, 30 : 671 - 671
  • [3] How to assess a cancer therapy? Feedback from the French HTA body on the ESMO-MCBS
    Grande, M.
    Fernandez, J.
    Dahmani, B.
    Stanel, S.
    Albin, N.
    Guillevin, L.
    Belorgey, C.
    D'Andon, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] Assessment of investigational new drugs (INDs) approved in USA and Europe after early phase trials using the ESMOmagnitude of clinical benefit scale (ESMO-MCBS)
    Moyers, J. T.
    Benjamin, D. J.
    Brazel, D.
    Kumar, P.
    Subbiah, V.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1144 - S1144
  • [5] CANCER DRUGS IN GERMANY: HTA DECISIONS OF NEW AND INNOVATIVE ONCOLOGY DRUGS IN GERMANY - AN ANALYSIS USING THE PRISMACCESS® DATABASE
    Mayer, F.
    Hodek, J.
    Walzer, S.
    VALUE IN HEALTH, 2018, 21 : S63 - S64
  • [6] Cost-effectiveness of front-line trials in metastatic colorectal cancer: Integrating the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) with the costs of drugs.
    Bonetti, Andrea
    Giuliani, Jcopo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States
    Salcher-Konrad, Maximilian
    Naci, Huseyin
    Davis, Courtney
    MILBANK QUARTERLY, 2020, 98 (04): : 1219 - 1256
  • [8] Cost-effectiveness of anti-angiogenic agents in second-line treatment for metastatic colorectal cancer. Integrating the EUROPEAN Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) with the costs of drugs
    Giuliani, J.
    Bonetti, A.
    ANNALS OF ONCOLOGY, 2017, 28 : 13 - 13
  • [9] THE ROLE OF AUSTRALIAN REGULATORY AUTHORITIES IN THE DEVELOPMENT OF NEW ANTI-CANCER DRUGS
    SNYDER, RD
    MEDICAL AND PEDIATRIC ONCOLOGY, 1983, 11 (03): : 192 - 192
  • [10] CANCER DRUGS IN EUROPE: A COMPARISON OF HTA PROCESSES AND DECISIONS FOR NEW AND INNOVATIVE ONCOLOGY THERAPIES IN FRANCE, GERMANY AND THE UK-AN ANALYSIS USING THE PRISMACCESS DATABASE
    Droeschel, D.
    Hartmann, M.
    Vollmer, L.
    Walzer, S.
    de Paz, B.
    VALUE IN HEALTH, 2016, 19 (07) : A761 - A761
12